Format

Send to

Choose Destination
Biomed Res Int. 2016;2016:1752854. doi: 10.1155/2016/1752854. Epub 2016 Apr 21.

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.

Author information

1
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Teaching Hospital, Strada di Fiume, 34149 Trieste, Italy.

Abstract

Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their potential utility as CVD biomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor activator of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as CVD biomarkers.

PMID:
27200369
PMCID:
PMC4856888
DOI:
10.1155/2016/1752854
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center